New drug aims to calm immune attacks on kidneys

NCT ID NCT06983028

Recruiting now Disease control Sponsor: Vera Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 study tests atacicept, a drug that may reduce immune system attacks on the kidneys. About 250 adults with various autoimmune kidney diseases (like IgA nephropathy or membranous nephropathy) will receive weekly injections. Researchers will check safety and measure changes in protein in the urine, a key sign of kidney damage.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: atacicept
What this could lead to: If successful, atacicept could offer a new treatment option to reduce protein leakage and preserve kidney function in people with autoimmune kidney diseases.
What could go wrong: This is an early Phase 2 trial with a moderate size of 250 people. It may not show clear benefit, and side effects or lack of efficacy could limit its use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FSGS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune disease focal segmental glomerulosclerosis glomerulonephritis idiopathic membranous glomerulonephritis idiopathic nephrotic syndrome IgA glomerulonephritis IgA nephropathy, susceptibility to, 1 immune system disorder immunoglobulin A vasculitis kidney disorder lipoid nephrosis macular corneal dystrophy myeloproliferative neoplasm nephritis nephrotic syndrome urinary system disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FSGS IGAN MCD NEPHROTIC SYNDROME PMN

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Vera Therapeutics
RECRUITING

Brisbane, California, 94005, United States

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.